Environmental Pollutants and Their Effects on Respiratory Allergy

May 21, 2021 updated by: Cindy Elizabeth de Lira-Quezada

Association Between Environmental Pollutants and Their Effects on Respiratory

In Latin America and the Caribbean, more than 100 million people are exposed to higher levels of pollution than those recommended by WHO. The objective of the study is to determine the relationship between exposure to environmental pollutants and the prevalence and exacerbation of respiratory allergy. It is an observational, prospective, longitudinal and descriptive study that will include subjects older than 6 years who come to the consultation of the Regional Center for Allergy and Clinical Immunology with a diagnosis of respiratory allergy, positive skin tests and who live in Monterrey and its metropolitan area. After verbal assent, the subject's address and work area will be registered, the Rhinitis Control Assessment Test and the Asthma Control Test as well as spirometry will be made. The geolocation of industries and avenues near the address and work area of subjects will be carried out, as well as the determination of pollutants and pollens by the Integral Monitoring System (SIMA) and the Pollen Sense device. Subsequently, the correlation between exposure to pollutants and respiratory allergy will be analyzed. Dispersion models will be built considering pollutants and climatic factors (precipitation, wind speed, humidity and temperature). By carrying out this project, it will be possible to contribute to the identification of the factors that lead to the development and exacerbation of allergic respiratory diseases and subsequently propose the implementation of measures for their control and recommendations for prevention to the population.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

93

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Cindy E. de Lira-Quezada, MD
  • Phone Number: +52 8110690275
  • Email: ce.dlira@gmail.com

Study Locations

  • Mexico
    • Nuevo Leon
      • Monterrey, Nuevo Leon, Mexico, 64460
        • Recruiting
        • Regional Center of Allergy and Clinical Immunology, Hospital Universitario "Dr. José Eleuterio González"
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Subjects older than 6 years of age, who attend the Regional Center of Allergy and Clinical Immunology of the University Hospital "Dr. José Eleuterio González "with a diagnosis of respiratory allergy (allergic rhinitis and asthma) and type I immunological hypersensitivity demonstrated by skin tests performed by an allergist and who live in Monterrey or its metropolitan area.

They will be invited to participate in the protocol and if they agree to be included, they will respond to informed verbal consent or assent.

Description

Inclusion Criteria:

  • Subjects over 6 years of age who attend the the Regional Center of Allergy and Clinical Immunology of the University Hospital "Dr. José Eleuterio González "with a diagnosis of respiratory allergy (allergic rhinitis and asthma) and type I immunological hypersensitivity demonstrated by skin tests by an allergist; and who live in the city of Monterrey and its metropolitan area.

Exclusion Criteria:

  • Subjects for whom it is not possible to perform a pulmonary function test or who have concomitant diseases such as COPD, heart disease or some other pathology that, in the opinion of the investigator, may cause confusion with respiratory symptoms. Patients with negative skin tests to aeroallergens.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Association of respiratory symptoms with exposure to pollutants and pollen
Time Frame: 1 year
To determine the relationship between exposure to environmental pollutants and the prevalence and exacerbation of respiratory allergy.
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Avenues with highest diesel exhaust particles and traffic related particles
Time Frame: 1 year
Locate the avenues with the highest flow and vehicular load releasing diesel removal particles (DEP) and traffic-related air pollutants (TRAP).
1 year
Location of the main industries that emit pollutants
Time Frame: 1 year
Location of the main industries that emit pollutants of particulate matter (PM), nitrogen dioxide (NO2), sulfur dioxide (SO2), carbon monoxide (CO) and ozone (O3).
1 year
Distance of greater exposure to pollutants
Time Frame: 1 year
To assess the relationship between the distance to PM, traffic-related air pollutants (TRAP) and diesel exhaust particles (DEP) with the prevalence of respiratory allergy symptoms with home and work address.
1 year
Time of pollutant exposure and association with respiratory symptoms
Time Frame: 1 year
Evaluate the relationship between the time of exposure to PM, NO2, SO2, O3, traffic-related air pollutants (TRAP) and diesel exhaust particles (DEP) with the prevalence of respiratory allergy symptoms.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cindy Elizabeth de Lira-Quezada

Collaborators

Medicina

Investigators

  • Study Director: Sandra N Gonzalez Diaz, MD,PhD, Head of the Allergy and Clinical Immunology Service

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 10, 2021

Primary Completion (Anticipated)

August 10, 2021

Study Completion (Anticipated)

August 10, 2022

Study Registration Dates

First Submitted

May 21, 2021

First Submitted That Met QC Criteria

May 21, 2021

First Posted (Actual)

May 26, 2021

Study Record Updates

Last Update Posted (Actual)

May 26, 2021

Last Update Submitted That Met QC Criteria

May 21, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AL2100004

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Allergic Rhinitis

Clinical Trials on pollutants and pollen

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe